Welcome to our dedicated page for Dianthus Therapeutics news (Ticker: DNTH), a resource for investors and traders seeking the latest updates and insights on Dianthus Therapeutics stock.
Dianthus Therapeutics develops next-generation therapies for severe autoimmune and inflammatory diseases as a clinical-stage biotechnology company. Its updates center on claseprubart, an investigational monoclonal antibody engineered to selectively inhibit the active form of C1s in the classical complement pathway, with programs in chronic inflammatory demyelinating polyneuropathy, generalized myasthenia gravis and multifocal motor neuropathy.
Recurring company news also covers FDA interactions and designations, clinical and preclinical program updates, financial results, public equity offerings, pre-funded warrants, and inducement equity grants under Nasdaq rules. Additional disclosures address DNTH212 and the company’s stated focus on rheumatology indications such as Sjögren’s disease, systemic lupus erythematosus and dermatomyositis.
Dianthus Therapeutics (DNTH) has completed enrollment for its Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG), exceeding the target with 65 patients enrolled. Top-line results are expected in September 2025. DNTH103 is a monoclonal antibody targeting the classical pathway by inhibiting the active C1s protein, designed for convenient self-administered subcutaneous injection every two weeks.
The trial focuses on patients with acetylcholine receptor antibody-positive gMG, with primary endpoints evaluating safety and tolerability. The U.S. gMG market exceeds 100,000 patients, with 85% having AChR autoantibody-driven disease. DNTH103 is also being evaluated in Phase 3 CAPTIVATE trial for CIDP and Phase 2 MoMeNtum trial for MMN, with results expected in 2H'26.
Dianthus Therapeutics, a clinical-stage biotech company focused on developing antibody complement therapeutics for autoimmune diseases, has announced its participation in two major investor events.
The company will be featured at:
- Baird Biotech Discovery Series - CEO Marino Garcia will join a fireside chat on May 6, 2025, at 1:30 p.m. EDT
- Bank of America 2025 Health Care Conference - Garcia will present a corporate overview on May 14, 2025, at 5:35 p.m. EDT and conduct one-on-one investor meetings
Both presentations will be accessible via webcast through the "News and Events" section of Dianthus Therapeutics' investor website.
Dianthus Therapeutics (DNTH) has reported its Q4 and FY 2024 financial results, highlighting significant progress in its clinical trials. The company's lead candidate DNTH103, a monoclonal antibody targeting the classical complement pathway, is advancing in multiple trials:
- Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) with top-line results expected in 2H'25
- Phase 3 CAPTIVATE trial in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) with interim analysis in 2H'26
- Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy (MMN) with results expected in 2H'26
Financial highlights include:
- Cash position of $357.0 million providing runway into 2H'27
- R&D expenses increased to $83.1 million in 2024
- Net loss of $85.0 million or $2.55 per share
- G&A expenses reached $25.0 million
Dianthus Therapeutics (NASDAQ: DNTH) has announced two key leadership appointments to strengthen its commercial capabilities. John C. King joins as Chief Commercial Officer, bringing over 25 years of global commercial leadership experience, particularly in complement inhibitor therapies for neuromuscular and hematological rare diseases.
King's notable achievements include launching the first approved biologic and C5 complement inhibitor in the Myasthenia Gravis market at Alexion, and leading commercial strategy for Ra Pharma's first FDA-approved self-administered subcutaneous biologic for gMG, which led to Ra Pharma's $2.5 billion acquisition by UCB.
Additionally, Sujay Kango, with 26+ years of industry experience, joins the Board of Directors. Kango's experience includes serving as CEO of Tmunity Therapeutics (acquired by Gilead) and EVP/CCO of Acceleron Pharma (acquired by Merck for $11.5B). The company also announced that Tomas Kiselak will transition from the Board of Directors.
Dianthus Therapeutics (Nasdaq: DNTH), a clinical-stage biotechnology company focused on developing next-generation antibody complement therapeutics for severe autoimmune diseases, has announced its participation in two upcoming investor conferences.
The company will participate in the TD Cowen 45th Annual Health Care Conference, where CEO Marino Garcia will conduct a fireside chat on March 5, 2025, at 11:50 a.m. ET in Boston. The presentation will be available via webcast on the company's website under the Investors section.
Additionally, Ryan Savitz, Chief Financial Officer and Chief Business Officer, will host one-on-one investor meetings at the Jefferies Biotech on the Bay Summit on March 12, 2025, in Miami.
Dianthus Therapeutics (Nasdaq: DNTH), a clinical-stage biotech company focused on developing antibody complement therapeutics for severe autoimmune diseases, has announced its upcoming participation in two major investor conferences in February 2025.
The company's CEO, Marino Garcia, will present at the Guggenheim SMID Cap Biotech Conference on February 6 at 9:00 a.m. ET in New York City, and the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12 at 3:20 p.m. ET, which will be held virtually.
Interested parties can access live webcasts of both presentations through the 'News and Events' section of the Investors page on Dianthus Therapeutics' website.
Dianthus Therapeutics (Nasdaq: DNTH), a clinical-stage biotech company focused on developing advanced antibody complement therapeutics for severe autoimmune diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference.
The company's CEO, Marino Garcia, will deliver a corporate overview presentation on Wednesday, January 15, 2025, at 9:00 a.m. PST / 12:00 p.m. EST in San Francisco. Interested parties can access a live webcast of the presentation through the 'News and Events' section of the Investors page on the Dianthus Therapeutics website.
Dianthus Therapeutics (NASDAQ: DNTH) reported Q3 2024 financial results and business updates. The company plans to initiate a pivotal Phase 3 trial of DNTH103 in CIDP by year-end 2024, while Phase 2 trials in gMG and MMN are ongoing with results expected in 2H'25 and 2H'26, respectively. Financial highlights include $342.6 million cash position providing runway into 2H'27, Q3 R&D expenses of $25.5 million, and a net loss of $25.2 million ($0.74 per share). DNTH103, their lead candidate, is designed for subcutaneous administration every two weeks in treating autoimmune disorders.
Dianthus Therapeutics (Nasdaq: DNTH) has announced its participation in three major healthcare investor conferences. CEO Marino Garcia will present corporate overviews at the Guggenheim Healthcare Innovation Conference (November 11, 1:30 p.m. ET, Boston), Jefferies Global Healthcare Conference (November 19, 9:00 a.m. GMT, London), and 7th Annual Evercore HealthCONx Conference (December 4, 10:50 a.m. ET, Coral Gables). Live webcasts will be available on the company's website under the Investors section.